| Title: |
Maximum 11C-methionine PET uptake as a prognostic imaging biomarker for newly diagnosed and untreated astrocytic glioma. |
| Authors: |
Nakajo, Kosuke1 (AUTHOR) kousuke19841984@yahoo.co.jp, Uda, Takehiro1 (AUTHOR), Kawashima, Toshiyuki1 (AUTHOR), Terakawa, Yuzo2 (AUTHOR), Ishibashi, Kenichi1,3 (AUTHOR), Tsuyuguchi, Naohiro1,4 (AUTHOR), Tanoue, Yuta1 (AUTHOR), Nagahama, Atsufumi1 (AUTHOR), Uda, Hiroshi1 (AUTHOR), Koh, Saya1 (AUTHOR), Sasaki, Tsuyoshi1 (AUTHOR), Ohata, Kenji1 (AUTHOR), Kanemura, Yonehiro5,6 (AUTHOR), Goto, Takeo1 (AUTHOR) |
| Source: |
Scientific Reports. 1/11/2022, Vol. 12 Issue 1, p1-10. 10p. |
| Subject Terms: |
*GLIOMAS, *KARNOFSKY Performance Status, *ISOCITRATE dehydrogenase, *PROGNOSIS, *PROGRESSION-free survival, *POSITRON emission tomography |
| Company/Entity: |
WORLD Health Organization |
| Abstract: |
This study aimed whether the uptake of amino tracer positron emission tomography (PET) can be used as an additional imaging biomarker to estimate the prognosis of glioma. Participants comprised 56 adult patients with newly diagnosed and untreated World Health Organization (WHO) grade II–IV astrocytic glioma who underwent surgical excision and were evaluated by 11C-methionine PET prior to the surgical excision at Osaka City University Hospital from July 2011 to March 2018. Clinical and imaging studies were retrospectively reviewed based on medical records at our institution. Preoperative Karnofsky Performance Status (KPS) only influenced progression-free survival (hazard ratio [HR] 0.20; 95% confidence interval [CI] 0.10–0.41, p < 0.0001), whereas histology (anaplastic astrocytoma: HR 5.30, 95% CI 1.23–22.8, p = 0.025; glioblastoma: HR 11.52, 95% CI 2.27–58.47, p = 0.0032), preoperative KPS ≥ 80 (HR 0.23, 95% CI 0.09–0.62, p = 0.004), maximum lesion-to-contralateral normal brain tissue (LN max) ≥ 4.03 (HR 0.24, 95% CI 0.08–0.71, p = 0.01), and isocitrate dehydrogenase (IDH) status (HR 14.06, 95% CI 1.81–109.2, p = 0.011) were factors influencing overall survival (OS) in multivariate Cox regression. OS was shorter in patients with LN max ≥ 4.03 (29.3 months) than in patients with LN max < 4.03 (not reached; p = 0.03). OS differed significantly between patients with IDH mutant/LN max < 4.03 and patients with IDH mutant/LN max ≥ 4.03. LN max using 11C-methionine PET may be used in prognostic markers for newly identified and untreated WHO grade II–IV astrocytic glioma. [ABSTRACT FROM AUTHOR] |
|
Copyright of Scientific Reports is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
